Takayasu Arteritis: Next-Line Treatment When Glucocorticoids and Conventional DMARD Therapy Have Not Achieved Sustained Remission
For patients with Takayasu arteritis whose disease remains active or relapses despite an initial course of glucocorticoids combined with a conventional DMARD, a defined escalation protocol guides the next clinical step.
Previous Treatment — Failure Condition
The prior regimen consisted of glucocorticoids (prednisone) combined with a conventional synthetic DMARD — methotrexate, mycophenolate mofetil, leflunomide, azathioprine, or cyclophosphamide. Escalation to this protocol is indicated when that regimen failed to reach the required treatment target: sustained remission — defined as absence of all clinical signs and symptoms of active Takayasu arteritis, normalisation of ESR and CRP, and no evidence of progressive vessel narrowing or dilatation, maintained for at least 6 months.
Next-Line Approach
This protocol introduces a biologic agent — from a class that targets a specific pro-inflammatory pathway — used in combination with glucocorticoids. It also specifies how both minor and major disease relapses are to be handled, and provides structured guidance on tapering glucocorticoids toward the lowest effective dose.
The complete agent selection, full management algorithm, and relapse response criteria are available in the structured protocol.
Treatment Target
Sustained remission: absence of all clinical signs and symptoms of active Takayasu arteritis, normalisation of ESR and CRP, and no evidence of progressive vessel narrowing or dilatation, maintained for at least 6 months.
References
DOI: 10.1136/annrheumdis-2019-215672
- Tocilizumab or TNF-inhibitors can be considered in case of relapsing or refractory disease despite conventional DMARD therapy.
- In relapsing TAK despite treatment with GC plus a conventional immunosuppressive agent, a TNF-inhibitor or TCZ can be used as second line agent.
- In case of major relapse (either with signs or symptoms of ischaemia or progressive vascular inflammation) we recommend reinstitution or dose escalation of GC therapy as recommended for new onset disease.
- For minor relapses we recommend an increase in GC dose at least to the last effective dose.
- The treatment target is sustained remission (absence of clinical signs and symptoms of active TAK associated with normal acute phase reactants) plus ability to taper GCs to the specified target without relapse.
- Absence of all clinical signs and symptoms attributable to active LVV and normalisation of ESR and CRP; in addition, for patients with extracranial disease there should be no evidence of progressive vessel narrowing or dilatation (frequency of repeat imaging to be decided on an individual basis).
View source ↗